References

1. MERREM® I.V. (meropenem for injection) Prescribing Information.

2. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24:311-320.

3. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis. 1997;28:157-163.

4. Mutnick AH, Rhomberg PR, Sader HS, et al. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother. 2004;53:290-296.

5. Rhomberg PR, Jones RN, Sader HS, et al. The MYSTIC Programme Study Group. Antimicrobial resistance rates and clonality results from the meropenem yearly susceptibility test information collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis. 2004;49:273-281.

6. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis. 2007;57:207-215.

7. Hoban DJ, Biedenbach DJ, Mutnick AH, et al. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis. 2003;45:279 285.

8. Data on file, DA-MER-06.

9. Ednie LM, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother. 2002;50:101-105.

10. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis Group: report and analysis of trends for 1997-2000. Clin Infect Dis. 2002;35(suppl I):S126-S134.

11. Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intraabdominal infections requiring surgery. J Antimicrob Chemother. 1995;36(suppl A):191-205.

12. Colardyn F, Faulkner KL, for the Meropenem Serious Infection Group Study. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother. 1996;38:523-537.

13. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbial Infect Dis. 1993;12:449-453